KLTO (Klotho Neurosciences) Shares Outstanding (EOP): 70.34 Mil (As of Sep. 2025)


KLTO Klotho Neurosciences Inc KLTO
22 GF Score
Price $0.52
! 1 Warning Sign
View Full Analysis

What is Klotho Neurosciences Shares Outstanding (EOP)?

Klotho Neurosciences KLTO 22 Shares Outstanding (EOP) is 70.34 Mil as of Sep. 2025. GuruFocus rates KLTO with a GF Score™ of 22/100. The stock has 1 warning sign investors should review.

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. Klotho Neurosciences's shares outstanding for the quarter that ended in Sep. 2025 was 70.34 Mil.

Klotho Neurosciences's quarterly shares outstanding increased from Jun. 2025 (52.70 Mil) to Sep. 2025 (70.34 Mil). It means Klotho Neurosciences issued new shares from Jun. 2025 to Sep. 2025 .

Klotho Neurosciences's annual shares outstanding increased from Dec. 2023 (15.13 Mil) to Dec. 2024 (27.08 Mil). It means Klotho Neurosciences issued new shares from Dec. 2023 to Dec. 2024 .


Klotho Neurosciences  (NAS:KLTO) Shares Outstanding (EOP) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred net income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


Klotho Neurosciences Shares Outstanding (EOP) Related Terms


Klotho Neurosciences Shares Outstanding (EOP) Historical Data

* Premium members only.

The historical data trend for Klotho Neurosciences's Shares Outstanding (EOP) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Klotho Neurosciences Shares Outstanding (EOP) Chart

Klotho Neurosciences Annual Data
Trend Dec21 Dec22 Dec23 Dec24
Shares Outstanding (EOP)
15.13 15.13 15.13 27.08

Klotho Neurosciences Quarterly Data
Dec21 Jun22 Dec22 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25
Shares Outstanding (EOP) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 21.26 27.08 28.51 52.70 70.34

KLTO vs KTTA, JUNS, ZEOX: Shares Outstanding (EOP) Comparison

For the Biotechnology subindustry, Klotho Neurosciences's Shares Outstanding (EOP), along with its competitors' market caps and Shares Outstanding (EOP) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Klotho Neurosciences Shares Outstanding (EOP) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Klotho Neurosciences's Shares Outstanding (EOP) distribution charts can be found below:

* The bar in red indicates where Klotho Neurosciences's Shares Outstanding (EOP) falls into.


KLTO
22GF Score
Klotho Neurosciences Inc KLTO
Shares Outstanding (EOP) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Klotho Neurosciences Shares Outstanding (EOP) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that end of period. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.

What does a Shares Outstanding (EOP) of 70.34 Mil mean?
Klotho Neurosciences (KLTO) has a Shares Outstanding (EOP) of 70.34 Mil as of Sep. 2025. The total shares a company has outstanding, at period-end. View historical data on Klotho Neurosciences and its competitors.
Is Klotho Neurosciences' Shares Outstanding (EOP) too high?
Klotho Neurosciences' current Shares Outstanding (EOP) is 70.34 Mil. Overall, Klotho Neurosciences has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Klotho Neurosciences' Shares Outstanding (EOP) compare to KTTA and JUNS?
Klotho Neurosciences' Shares Outstanding (EOP) of 70.34 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shares Outstanding (EOP) for a Biotechnology company?
A good Shares Outstanding (EOP) depends on the Biotechnology industry context. However, Shares Outstanding (EOP) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shares Outstanding (EOP) mean?
A high Shares Outstanding (EOP) can signal that a stock is expensive relative to its fundamentals. The total shares a company has outstanding, at period-end. View historical data on Klotho Neurosciences and its competitors. Klotho Neurosciences's current Shares Outstanding (EOP) is 70.34 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Klotho Neurosciences stock overvalued right now?
Klotho Neurosciences (KLTO) has a current Shares Outstanding (EOP) of 70.34 Mil. The current Shares Outstanding (EOP) is 70.34 Mil. Klotho Neurosciences' overall GF Score™ is 22/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shares Outstanding (EOP) calculated?
Shares Outstanding (EOP) is calculated from a company's financial statements. For Klotho Neurosciences (KLTO), the current Shares Outstanding (EOP) is 70.34 Mil as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Klotho Neurosciences Business Description

Address 13576 Walnut Street, Suite A, Omaha, NE, USA, 68144
Klotho Neurosciences Inc is in the development of essential medicines for the treatment of chronic diseases: Cancer, Cardiovascular, and Neurodegenerative disorders. The Company currently has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform that uses biologic therapies to treat cancer, and a proprietary, patented gene therapy platform which uses a gene therapy approach to introduce a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases. Company pipeline includes KLTO 101, KLTO 202, KLTO 301.
22GF Score

Get the complete analysis for KLTO

Shares Outstanding (EOP) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.52
Price